Clinical Trial Update: A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 trial of sasanlimab in non-muscle invasive bladder cancer has posted results and the study is currently listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Sasanlimab (sasanlimab)

Snippet

Sponsor: Pfizer | Conditions: Non-muscle Invasive Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-22